From histology to micro-CT: Measuring and modeling resorption cavities and their relation to bone competence

Table 3 Change of eroded surface, erosion depth and wall thickness with treatment for postmenopausal osteoporosis as reported in literature

Treatment for PmOP	Parameter	Change	Values11Significantly lower then no treatment2Significantly higher then no treatment
Bisphosphonates (oral/IV ibandronate, alendronate, risendronate)	EV/BV (%)	b	0.40 (0.1)-0.50 (0.1)[60]
	ES/BS (%)	b	2.2 (0.4)-2.6 (0.5)[60]
			5.3 (2.75)[67]
			1.29 (90%CI: 1.04-1.95)-1.62 (90%CI: 1.32-1.88)[66]
	E.De (μm)	b	13.4 (1.0)-16.2 (1.0)[60]
			45.6 (9.45)[67]
	W.Th (μm)	b	30.0 (1.0)-31.4 (1.0)[60]
			41.6 (4.86)[67]
Strontium ranelate	ES/BS (%)	b	2.92 (1.48-3.89)[52]
Strontium ranelate 6 m	ES/BS (%)	↓	1.21 (0.21)1[74]
hPTH (1-34)	ES/BS (%)	↑	0.78 (0.11)[74]
(teriparatide)			10.1 (4.9)2-11.8 (7.1)2[71]
			3.51 (Q 2.67-5.64)-4.0 (Q 2.8-6.0)[72]
	W.Th (μm)	b	22 (5)-28 (7)[71]
PTH (1-84)	ES/BS (%)	↑b	1.75 (0.35)[73]
	W.Th (μm)	b	33.1 (1.4)[73]

Significant difference vs control (no treatment) indicated (¹Significantly lower than control;

²Significantly higher than control). Values as mean ± SD, mean (95%CI), mean [10^th-90^th percentile], mean[Q 1^st-3^rd quartile];

^bAlso indicated in table is whether the parameters increase (↑), decrease (↓) due to the treatment or stay constant. When more than one value is reported for the same reference, it concerns measurements at different time points or different doses. ES/BS: Eroded surface; E.De: Erosion depth; W.Th: Wall thickness; PmOP: Postmenopausal osteoporosis.